The impact of the Polish mass breast cancer screening program on prognosis in the Pomeranian ProvinceShow others and affiliations
2017 (English)In: Archives of Medical Science, ISSN 1734-1922, E-ISSN 1896-9151, Vol. 13, no 2, p. 441-447Article in journal (Refereed) Published
Abstract [en]
Introduction: Mammographic screening results in diagnosis of less advanced breast cancer (BC). A meta-analysis of randomized clinical trials confirmed that BC screening reduces mortality. In 2007, the National Breast Cancer Screening Program (NBCSP) was established in Poland with the crucial aim of reducing mortality from BC. The purpose of this study was to assess the impact of participation in the NBCSP on prognosis. Material and methods: A single institution, non-randomized retrospective study was undertaken. The study population comprised 643 patients with BC treated in the Department of Surgical Oncology (DSO) at the Medical University of Gdansk over a 4-year period, from 01.01.2007 until 31.12.2010. Patients were divided into two groups: group A-patients who participated in the NBCSP (n = 238, 37.0%); and group B-patients who did not participate in the NBCSP (n = 405, 63.0%). Results: Statistical analysis revealed that group A displayed a less advanced MCC stage (more patients in AJCC stage I, p = 0.002), lower tumor diameter (more patients with pT1, p = 0.006, and pT < 15 mm, p = 0.008) and a lower incidence of metastases to axillary lymph nodes (more patients with pNO, p = 0.01). From 2009 to 2010 the NBCSP revealed a statistically significant benefit significantly more patients in stage 0 + I (60.7% vs. 48.8%, p = 0.018) and with tumors pT < 15 mm (48.8% vs. 35.1%, p = 0.011) were observed in group A. Conclusions: The study results revealed the beneficial impact of the NBCSP. Superior prognostic factors and favorable staging were observed in women who participated in the NBCSP.
Place, publisher, year, edition, pages
Termedia Publishing House Ltd. , 2017. Vol. 13, no 2, p. 441-447
Keywords [en]
breast cancer, screening, mass screening, prognostic factors, MCC staging, prognosis
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:liu:diva-140867DOI: 10.5114/aoms.2016.60387ISI: 000395365500022PubMedID: 28261300OAI: oai:DiVA.org:liu-140867DiVA, id: diva2:1140928
2017-04-192017-09-132020-08-31Bibliographically approved